BioSpace News Archive

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results.

PLOS ONE Publishes Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx ® Activates Systems in Brain Key to Attentional Functioning.

ADC Therapeutics SA today unveiled its first Environmental, Social and Governance (ESG) report detailing the Company’s focus on patient care and sustainable innovation.

Intellia Therapeutics, Inc. today announced that it will be hosting two virtual investor events in February.

Arbutus Biopharma Corporation today announced that it has scheduled its fourth quarter and year end 2021 financial results and corporate update for Thursday, March 3, 2022.

XOMA Corporation announced today its Chief Executive Officer, Jim Neal, will present at the Aegis Capital Corp Virtual Conference on February 24, 2022 at 11:00 AM ET.

Enveric Biosciences is working with the University of Calgary’s Hotchkiss Brain Institute (“HBI”) to establish a groundbreaking clinical trial of EVM-101 for the treatment of Cancer Related Distress (“CRD”).

Partner Therapeutics, Inc. (PTx) today announced a milestone-based Other Transaction Agreement (OTA) with the United States Department of Defense (DoD) to fund development and regulatory activities to support an sBLA of Leukine.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced positive interim results from AROHIF21001, a Phase 1b dose-finding clinical study of ARO-HIF2, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma (ccRCC).

Maze Therapeutics today announced the initiation of dosing in the company’s Phase 1 clinical trial of MZE001 in healthy volunteers.